John M. Taladay

John M. Taladay is Co-Chair of the Antitrust practice of Baker Botts. He is well-recognized as a leading global antitrust practitioner, known for his work in gaining merger approvals, defending criminal cartel investigations, litigating civil antitrust cases and managing complex international competition matters.

In working closely with the U.S. Federal Trade Commission, the U.S. Department of Justice Antitrust Division, the European Commission and other international agencies, Mr. Taladay has extensive experience in gaining merger clearances particularly in the technology, media, telecommunications, consumer products, software and pharmaceutical sectors and traditional industries including the automotive, airline, primary metals, agriculture, food, chemicals and electronics sectors.

Mr. Taladay has also led the defense of U.S. and foreign corporations and individuals in dozens of major cartel matters including antitrust grand jury investigations into allegations of price fixing, bid-rigging, market allocation and related offenses. He has navigated corporate clients through a range of cartel representation strategies from steadfast defense to leniency application to formal non-prosecution treatment. His litigation work includes acting as lead counsel in numerous civil antitrust class action and other litigation matters involving nearly all aspects of the antitrust laws.

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,
Read More

If Private Sector R&D Is the Future, IP Policy Must Catch Up

By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely
Read More

Don’t Tax Invention: The Risks of a Patent Tax

By Sujai Shivakumar and Chris Borges The Commerce Department is reportedly considering a novel revenue-raising idea to address the national debt: a “patent tax.” Under this proposal, patent holders would be required to pay the federal government between 1 and 5 percent of their patents’ assessed value each year. While the
Read More